Hjem › Lungekreft › Michigan › Detroit
Kliniske studier for Lungekreft i Detroit, MI
20 studier for Lungekreft søker deltakere på steder i og rundt Detroit (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
The Vanguard Study: Testing a New Way to Screen for Cancer
RekruttererFrivillige helsepersonell ønskes velkommen
- Henry Ford Hospital, Detroit
- Henry Ford Medical Center - Detroit Northwest, Detroit
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruttererFase 3
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
RekruttererFase 3
- Henry Ford Health Saint John Hospital, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekruttererFase 3
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RekruttererFase 3
- Karmanos Cancer Institute, Detroit
- Henry Ford Health, Detroit
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
RekruttererFase 2/3
- Local Institution - 0405, Detroit
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekruttererFase 1
- Karmanos Cancer Institiute, Detroit
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
RekruttererFase 1
- Henry Ford Cancer - Detroit, Detroit
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RekruttererFase 3
- Henry Ford Cancer Institute, Detroit
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
RekruttererFase 3
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
RekruttererFase 3
- Wayne State University/Karmanos Cancer Institute, Detroit
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RekruttererFase 1/2
- Karmanos Cancer Institute, Detroit
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RekruttererFase 1/2
- Henry Ford Cancer Institute, Detroit
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
RekruttererFase 2
- Henry Ford Cancer- Detroit, Detroit
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
RekruttererFase 1/2
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
RekruttererFase 2
- Karmanos Cancer Institute, Detroit
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruttererFase 2
- Henry Ford Hospital, Detroit
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
RekruttererFase 1/2
- Karmanos Cancer Institute, Detroit
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
RekruttererFase 1/2
- Henry Ford Health, Detroit
Lungekreft-studier i andre byer
- Houston, TX78 studier
- Boston, MA62 studier
- New York City, NY60 studier
- Los Angeles, CA45 studier
- Arlington, VA41 studier
- Washington, DC41 studier
- Chicago, IL41 studier
- Baltimore, MD40 studier
- Nashville, TN40 studier
- St. Louis, MO39 studier
- Columbus, OH37 studier
- Philadelphia, PA36 studier
Andre studier i Detroit
- Ikke-småcellet lungekreft44 studier
- Brystkreft33 studier
- Kreft (alle typer)29 studier
- Kolorektal kreft26 studier
- Eggstokkreft26 studier
- Metastatisk kreft24 studier
- Prostatakreft22 studier
- Endometriekreft21 studier
- Multipelt myelom19 studier
- Mavekreft16 studier
- Plateepitelcancer i hode og hals15 studier
- Akut myelogen leukemi14 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.